Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) Director Thilo Schroeder acquired 100,000 shares of the firm's stock in a transaction that occurred on Friday, March 10th. The stock was bought at an average price of $20.46 per share, with a total value of $2,046,000.00. Following the completion of the acquisition, the director now directly owns 1,553,134 shares of the company's stock, valued at $31,777,121.64. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Thilo Schroeder also recently made the following trade(s):
Get Revolution Medicines alerts:- On Tuesday, March 7th, Thilo Schroeder acquired 550,000 shares of Revolution Medicines stock. The shares were bought at an average cost of $22.00 per share, for a total transaction of $12,100,000.00.
Revolution Medicines Stock Down 4.3 %
Shares of RVMD stock opened at $20.76 on Friday. The company has a 50 day moving average of $25.62 and a 200-day moving average of $22.61. Revolution Medicines, Inc. has a 12-month low of $14.08 and a 12-month high of $31.37. The firm has a market cap of $1.88 billion, a P/E ratio of -6.70 and a beta of 1.49.
Revolution Medicines (NASDAQ:RVMD – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.21. Revolution Medicines had a negative net margin of 702.95% and a negative return on equity of 41.17%. The business had revenue of $15.33 million during the quarter, compared to analyst estimates of $6.75 million. As a group, equities analysts expect that Revolution Medicines, Inc. will post -3.67 EPS for the current year.
Analyst Upgrades and Downgrades
RVMD has been the topic of a number of research analyst reports. Needham & Company LLC increased their price objective on shares of Revolution Medicines from $32.00 to $38.00 and gave the stock a "buy" rating in a research report on Tuesday, February 28th. The Goldman Sachs Group raised their price target on shares of Revolution Medicines from $20.00 to $23.00 and gave the company a "neutral" rating in a research report on Wednesday, March 1st. HC Wainwright raised their price target on shares of Revolution Medicines from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, December 8th. Oppenheimer raised their price target on shares of Revolution Medicines from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Tuesday, February 28th. Finally, Guggenheim reissued a "buy" rating and set a $38.00 target price on shares of Revolution Medicines in a research report on Tuesday, February 28th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $32.25.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of RVMD. EcoR1 Capital LLC boosted its holdings in Revolution Medicines by 147.5% in the 4th quarter. EcoR1 Capital LLC now owns 4,458,731 shares of the company's stock valued at $106,207,000 after purchasing an additional 2,656,884 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Revolution Medicines by 25.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,984,002 shares of the company's stock worth $137,725,000 after acquiring an additional 1,416,990 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Revolution Medicines by 63.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,652,628 shares of the company's stock worth $72,030,000 after purchasing an additional 1,414,774 shares during the last quarter. Bellevue Group AG lifted its stake in Revolution Medicines by 38.3% in the third quarter. Bellevue Group AG now owns 4,680,162 shares of the company's stock worth $92,293,000 after purchasing an additional 1,296,900 shares during the last quarter. Finally, State Street Corp lifted its stake in Revolution Medicines by 39.3% in the third quarter. State Street Corp now owns 4,312,134 shares of the company's stock worth $85,035,000 after purchasing an additional 1,217,152 shares during the last quarter.
About Revolution Medicines
(Get Rating)
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on Revolution Medicines (RVMD)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.